Cart
sales@molnova.com
Lartesertib
CAS No. 2495096-26-7
Lartesertib( —— )
Catalog No. M35661 CAS No. 2495096-26-7
Lartesertib (ATM Inhibitor-5) is an inhibitor of serine/threonine protein kinase ATM with potential anticancer activity for the study of lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 201 | Get Quote |
|
| 5MG | 312 | Get Quote |
|
| 10MG | 534 | Get Quote |
|
| 25MG | 1003 | Get Quote |
|
| 50MG | 1674 | Get Quote |
|
| 100MG | 2538 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLartesertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionLartesertib (ATM Inhibitor-5) is an inhibitor of serine/threonine protein kinase ATM with potential anticancer activity for the study of lung cancer.
-
DescriptionLartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetATM/ATR
-
RecptorATM/ATR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2495096-26-7
-
Formula Weight448.45
-
Molecular FormulaC23H21FN6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (222.99 mM)
-
SMILESCOc1cncc(F)c1-n1c2c(cnc3cc(OC)c(cc23)-c2cn(C)nc2C)n(C)c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Alessandra AMBRUOSI, et al. Pharmaceutical preparation. WO2022058351A1.
molnova catalog
related products
-
Arg-Gly-Asp TFA
RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to?integrins.
-
AZ-31
A potent, highly selective and orally active ATM inhibitor with enzyme IC50 of <1.2 nM, cell IC50 of 46 nM.
-
AZD1390
AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM.Brain Cancer,Phase 1 Clinical
